Literature DB >> 22675128

Efficient quantification of HIV-1 in heparin plasma spiked with cultured HIV-1 by the Roche Cobas TaqMan and Abbott RealTime HIV-1 tests.

Linda L Jagodzinski1, Holly R Weston, Ying Liu, Robert J O'Connell, Sheila A Peel.   

Abstract

The current automated real-time HIV-1 viral load assays, the Roche Cobas AmpliPrep/Cobas TaqMan test and the Abbott RealTime test, are FDA cleared for use with EDTA plasma. We show that both real-time reverse transcription-PCR (RT-PCR) tests reliably quantify HIV-1 RNA in heparin plasma specimens spiked with HIV-1 isolate MN.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22675128      PMCID： PMC3421498          DOI： 10.1128/JCM.00706-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  14 in total

1.  Titration of heparinase for removal of the PCR-inhibitory effect of heparin in DNA samples.

Authors:  A C Taylor
Journal:  Mol Ecol       Date:  1997-04       Impact factor: 6.185

2.  Detection of HIV-1 RNA in heparinized plasma of HIV-1 seropositive individuals.

Authors:  H Imai; O Yamada; S Morita; S Suehiro; T Kurimura
Journal:  J Virol Methods       Date:  1992-02       Impact factor: 2.014

3.  Effectiveness of highly-active antiretroviral therapy by race/ethnicity.

Authors:  Michael J Silverberg; Scott A Wegner; Mark J Milazzo; Rosemary G McKaig; Carolyn F Williams; Brian K Agan; Adam W Armstrong; Stephen J Gange; Clifton Hawkes; Robert J O'Connell; Sunil K Ahuja; Matthew J Dolan
Journal:  AIDS       Date:  2006-07-13       Impact factor: 4.177

Review 4.  Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.

Authors:  J Lew; P Reichelderfer; M Fowler; J Bremer; R Carrol; S Cassol; D Chernoff; R Coombs; M Cronin; R Dickover; S Fiscus; S Herman; B Jackson; J Kornegay; A Kovacs; K McIntosh; W Meyer; N Michael; L Mofenson; J Moye; T Quinn; M Robb; M Vahey; B Weiser; T Yeghiazarian
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

5.  An optimized sensitive method for quantitation of DNA/RNA viruses in heparinized and cryopreserved plasma.

Authors:  Ming Ding; Arlene Bullotta; Lori Caruso; Phalguni Gupta; Charles R Rinaldo; Yue Chen
Journal:  J Virol Methods       Date:  2011-05-17       Impact factor: 2.014

6.  Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection.

Authors:  R J Rodriguez; D E Dayhoff; G Chang; S A Cassol; D L Birx; A W Artenstein; N L Michael
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-05-01

7.  Host determinants of HIV-1 control in African Americans.

Authors:  Kimberly Pelak; David B Goldstein; Nicole M Walley; Jacques Fellay; Dongliang Ge; Kevin V Shianna; Curtis Gumbs; Xiaojiang Gao; Jessica M Maia; Kenneth D Cronin; Shehnaz K Hussain; Mary Carrington; Nelson L Michael; Amy C Weintrob
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

8.  Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR.

Authors:  R E Dickover; S A Herman; K Saddiq; D Wafer; M Dillon; Y J Bryson
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

9.  Techniques for the evaluation of nucleic acid amplification technology performance with specimens containing interfering substances: efficacy of boom methodology for extraction of HIV-1 RNA.

Authors:  D J Witt; M Kemper
Journal:  J Virol Methods       Date:  1999-04       Impact factor: 2.014

10.  Immunologic and virologic events in early HIV infection predict subsequent rate of progression.

Authors:  Anuradha Ganesan; Pratip K Chattopadhyay; Tess M Brodie; Jing Qin; Wenjuan Gu; John R Mascola; Nelson L Michael; Dean A Follmann; Mario Roederer
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.